Fosfructose trisodium - Questcor Pharmaceuticals
Alternative Names: Cordox; CPC-111 - Questcor PharmaceuticalsLatest Information Update: 13 Oct 2005
Price :
$50 *
At a glance
- Originator Questcor Pharmaceuticals
- Class Anti-ischaemics; Heart failure therapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Heart failure; Heart transplant rejection; Perioperative ischaemia; Reperfusion injury; Transplant rejection; Vaso-occlusive crisis
Most Recent Events
- 13 Oct 2005 Discontinued - Phase-I for Heart failure in China (IV)
- 13 Oct 2005 Discontinued - Phase-I for Heart transplant rejection in Europe (unspecified route)
- 13 Oct 2005 Discontinued - Phase-II for Heart failure in United Kingdom (IV)